BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 3010811)

  • 1. Treatment of acid-peptic diseases by inhibition of gastric H+,K+-ATPase.
    McArthur KE; Jensen RT; Gardner JD
    Annu Rev Med; 1986; 37():97-105. PubMed ID: 3010811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inhibition of H+/K+-ATPase in the parietal cell with omeprazole: a new principle of gastric acid inhibition].
    Lamers CB
    Ned Tijdschr Geneeskd; 1985 Apr; 129(15):679-82. PubMed ID: 2986019
    [No Abstract]   [Full Text] [Related]  

  • 4. Omeprazole: a comprehensive review.
    Massoomi F; Savage J; Destache CJ
    Pharmacotherapy; 1993; 13(1):46-59. PubMed ID: 8437967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Omeprazole--a drug-blocking proton pump of the parietal cells of the stomach].
    Sosnowski M
    Pol Tyg Lek; 1985 Dec 23-30; 40(51-52):1469-72. PubMed ID: 3008128
    [No Abstract]   [Full Text] [Related]  

  • 6. [Substituted benzimidazoles--a new dimension in ulcer therapy?].
    Fimmel CJ; Blum AL
    Wien Klin Wochenschr; 1984 Feb; 96(4):149-53. PubMed ID: 6324498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lansoprazole: a comprehensive review.
    Zimmermann AE; Katona BG
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility and safety of omeprazole.
    Walan A
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():107-11. PubMed ID: 2657279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical perspectives of drugs inhibiting acid secretion--H+K+-ATPase inhibitors.
    Walan A
    Scand J Gastroenterol Suppl; 1986; 125():50-4. PubMed ID: 3029857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Are proton pump inhibitors safe?].
    Creutzfeldt W
    Internist (Berl); 1994 Dec; 35(12):1137-46. PubMed ID: 7883517
    [No Abstract]   [Full Text] [Related]  

  • 11. Present experiences with omeprazole in the Zollinger-Ellison syndrome.
    Lamers CB
    Scand J Gastroenterol Suppl; 1986; 118():123-8. PubMed ID: 3460167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of gastric proton pump inhibitors on gastric secretion and peptic ulcers].
    Okabe S
    Nihon Yakurigaku Zasshi; 1986 Apr; 87(4):351-60. PubMed ID: 2873085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease.
    Naesdal J; Bodemar G; Walan A
    Scand J Gastroenterol; 1984 Oct; 19(7):916-22. PubMed ID: 6531660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Indications and use of omeprazole in esophago-gastro-duodenal diseases].
    Martín de Argila C; Boixeda de Miquel D; Moreira Vicente V; García Plaza A
    Rev Clin Esp; 1999 Nov; 199(11):729-39. PubMed ID: 10638238
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
    Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Substituted benzimidazole, inhibiting substance of K+/H+ ATPase of parietal cells--a new principle in the treatment of peptic ulcer].
    Sewing KF
    Internist (Berl); 1983 Dec; 24(12):680-3. PubMed ID: 6319314
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lansoprazole--profile of a new proton pump inhibitor].
    Seifert E
    Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.
    Lambers CB; Lind T; Moberg S; Jansen JB; Olbe L
    N Engl J Med; 1984 Mar; 310(12):758-61. PubMed ID: 6142418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K(+)-ATPase inhibitors.
    Shamburek RD; Schubert ML
    Gastroenterol Clin North Am; 1992 Sep; 21(3):527-50. PubMed ID: 1355465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical treatment of peptic ulcers.
    Deveney CW; Deveney KE
    Surg Annu; 1985; 17():219-33. PubMed ID: 3883541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.